Glaukos Corporation (GKOS)
- Previous Close
98.95 - Open
99.49 - Bid 66.00 x 800
- Ask 125.00 x 800
- Day's Range
98.31 - 101.24 - 52 Week Range
45.38 - 102.33 - Volume
351,098 - Avg. Volume
514,545 - Market Cap (intraday)
5.074B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-2.78 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
106.55
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
www.glaukos.comRecent News: GKOS
Performance Overview: GKOS
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GKOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GKOS
Valuation Measures
Market Cap
5.07B
Enterprise Value
5.16B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.56
Price/Book (mrq)
10.99
Enterprise Value/Revenue
16.40
Enterprise Value/EBITDA
-62.87
Financial Highlights
Profitability and Income Statement
Profit Margin
-42.79%
Return on Assets (ttm)
-7.96%
Return on Equity (ttm)
-27.16%
Revenue (ttm)
314.71M
Net Income Avi to Common (ttm)
-134.66M
Diluted EPS (ttm)
-2.78
Balance Sheet and Cash Flow
Total Cash (mrq)
295.43M
Total Debt/Equity (mrq)
83.59%
Levered Free Cash Flow (ttm)
-32.22M
Research Analysis: GKOS
Company Insights: GKOS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GKOS
GKOS: Lowering target price to $83.00
GLAUKOS CORP has an Investment Rating of SELL; a target price of $83.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetGKOS: Raising target price to $84.00
GLAUKOS CORP has an Investment Rating of SELL; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetGKOS: What does Argus have to say about GKOS?
GLAUKOS CORP has an Investment Rating of SELL; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetGKOS: What does Argus have to say about GKOS?
GLAUKOS CORP has an Investment Rating of SELL; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target